05889nam 2201597z- 450 991056647180332120220506(CKB)5680000000037662(oapen)https://directory.doabooks.org/handle/20.500.12854/81021(oapen)doab81021(EXLCZ)99568000000003766220202205d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierEndothelial Dysfunction: From Pathophysiology to Novel Therapeutic ApproachesBaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (368 p.)3-0365-3036-3 3-0365-3037-1 Dear colleagues, This Special Issue, "Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches", focuses on the pathophysiology of endothelial dysfunction, new biomarkers for endothelial dysfunction related to cardiovascular disorders or tumors, and novel therapeutic approaches for endothelial dysfunctions. Vascular endothelium is an active tissue and plays a crucial role in the maintenance of vascular homeostasis. Chronic exposure to risk factors, such as hypertension, high cholesterolemia, or oxidative stress, induces endothelial dysfunctions and results in a loss of endothelial integrity, smooth muscle cell proliferation, and macrophage recruitment. The pathophysiology of endothelial dysfunction (ED) is complex and multi-factorial factors are involved, such as oxidative stress or chronic inflammation. The primary prevention of cardiovascular risk factors and endothelial dysfunctions, as well as the early detection of or molecular imaging techniques for endothelial dysfunction, helps to prevent the development of cardiovascular disorders. Novel therapeutic approaches or drug delivery systems for endothelial dysfunctions have had promising beneficial effects in preclinical or clinical levels by affecting the progression of atherosclerotic changes, tumor angiogenesis, and host-immune reactions near tumor environments.Endothelial DysfunctionBiotechnologybicsscTechnology: general issuesbicsscADMAaerobic exercisealdehyde dehydrogenase-2angiogenesisAPE1/Ref-1ApoE knockout mouseargininearginine paradoxatherosclerosisatorvastatinBH4blood pressurecardiovascular diseasecardiovascular diseasescardiovascular risk factorschronic kidney diseasechronic venous insufficiencyCKDcompound 9COVID-19CV riskdiabetesdietary supplementsdyslipidemiaelectronegative LDLelectronegative low-density lipoproteinEndoMTendothelial cellendothelial cell dysfunctionendothelial cellsendothelial disfunctionendothelial dysfunctionendothelial to mesenchymal transitionendotheliumeNOS uncouplingepigenetic factorsepigeneticsessential hypertensiongalectin-3glycated HDLglycated LDLglycated lipoproteinsglycolysishealingheart failureHIF-1αhigh-fat dietshyperglycemiahyperphosphatemiahypertensioninflammageinginflammationinsulin resistanceischemiaL-arginineL5 LDLLDL(-)LDL(−)lectin-like oxLDL receptor-1low-level laser therapyLOX-1lung diseasemacrophage polaritymacrophagesmetabolismmetforminmolecular mechanismsMRI (magnetic resonance imaging)myocardial infarctionn/aNADPHnargenicin A1neurovascular diseaseneutrophil/lymphocyte rationitric oxideoxidative stressoxidized LDLoxLDLpathological angiogenesisPCSK9peripheral artery diseasephototherapyplaque burdenprolyl oligopeptidase (POP)pulmonary fibrosispulmonary hypertensionserological biomarkersserum γ-glutamyltransferasesubcellular localizationTGF-βtherapeutic approachestumor microenvironmenturemic toxinsvascular calcificationvascular diseasevascular inflammationvascular smooth muscle cellsvasoactive factorsVCAM-1VEGFVEGFR2VSMCsBiotechnologyTechnology: general issuesJeon Byeong Hwaedt1319556Jeon Byeong HwaothBOOK9910566471803321Endothelial Dysfunction: From Pathophysiology to Novel Therapeutic Approaches3033962UNINA